47.07
+2.295(+5.13%)
Currency In USD
| Previous Close | 44.77 |
| Open | 44.17 |
| Day High | 47.14 |
| Day Low | 44.17 |
| 52-Week High | 60.92 |
| 52-Week Low | 35.7 |
| Volume | 313,228 |
| Average Volume | 689,872 |
| Market Cap | 2.03B |
| PE | -16.87 |
| EPS | -2.79 |
| Moving Average 50 Days | 52.52 |
| Moving Average 200 Days | 47.14 |
| Change | 2.3 |
If you invested $1000 in Soleno Therapeutics, Inc. (SLNO) 10 years ago, it would be worth $373.53 as of December 26, 2024 at a share price of $47.065. Whereas If you bought $1000 worth of Soleno Therapeutics, Inc. (SLNO) shares 5 years ago, it would be worth $1,063.62 as of December 26, 2024 at a share price of $47.065.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
GlobeNewswire Inc.
Dec 17, 2024 9:05 PM GMT
Up to $200 million financing, includes $50 million upfrontREDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 1:00 PM GMT
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that managemen
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
GlobeNewswire Inc.
Nov 26, 2024 1:30 PM GMT
PDUFA target action date extended by three months to March 27, 2025REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics